Advertisement

HER2 in Uterine Serous Carcinoma: Testing platforms and implications for targeted therapy

Published:September 13, 2022DOI:https://doi.org/10.1016/j.ygyno.2022.09.006

      Highlights

      • IHC and CISH testing platforms have high concordance in identifying HER2+ uterine serous carcinoma.
      • NGS testing for ERBB2 amplification has a low sensitivity but high PPV in identifying HER2+ uterine serous carcinoma.
      • No major differences in gene alterations or immunotherapy biomarkers identified between HER2+ and negative tumors.

      Abstract

      Objective

      HER2 is an important prognostic and therapeutic target in uterine serous carcinoma (USC). Optimal HER2 testing platforms have not been defined and guidelines for testing have changed over time. Our objective is to assess the concordance of HER2 positivity based on chromogenic in situ hybridization (CISH), immunohistochemistry (IHC), and next generation sequencing (NGS) and to determine the rate of downstream mutations that may affect response to HER2 directed therapy.

      Methods

      Utilizing the Caris tumor registry, 2192 USC tumors were identified and analyzed using NGS (NextSeq, 592 Genes and WES, NovaSEQ), IHC, and CISH. PD-L1 expression was tested by IHC. Microsatellite instability was tested by fragment analysis, IHC, and NGS. Tumor mutational burden (TMB) was measured by totaling somatic mutations per tumor. HER2 positivity through IHC and CISH was determined based on 2007 and 2018 ASCO/CAP HER2 breast cancer guidelines.

      Results

      There was a higher rate of HER2 positivity by IHC when using the 2018 guidelines compared to the 2007 guidelines (16.3% vs 12.3%). Concordance between IHC and CISH was 98.9%. ERBB2 amplification was identified by NGS in 10.5% of tumors. Compared to CISH results, this corresponds to a concordance rate of 91.6% and a positive predictive value (PPV) of 60.3%. Single gene alterations in HER2 amplified tumors that may implicate HER2 therapy resistance included PI3K (33.1%), KRAS (2.5%), and PTEN (1.3%).

      Conclusions

      There was high concordance between HER2 positivity based on CISH and IHC. Rate of HER2 positivity is the lowest by NGS. Ultimately these testing platforms need to be validated by response to targeted therapy.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hamilton C.A.
        • Cheung M.K.
        • Osann K.
        • Chen L.
        • Teng N.N.
        • Longacre T.A.
        • et al.
        Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers.
        Br. J. Cancer. 2006; 94: 642-646
        • Tashiro H.
        • Isacson C.
        • Levine R.
        • Kurman R.J.
        • Cho K.R.
        • Hedrick L.
        p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis.
        Am. J. Pathol. 1997; 150: 177-185
        • Cancer Genome Atlas Research N
        • Kandoth C.
        • Schultz N.
        • Cherniack A.D.
        • Akbani R.
        • Liu Y.
        • et al.
        Integrated genomic characterization of endometrial carcinoma.
        Nature. 2013; 497: 67-73
        • Cavalot A.
        • Martone T.
        • Roggero N.
        • Brondino G.
        • Pagano M.
        • Cortesina G.
        Prognostic impact of HER-2/neu expression on squamous head and neck carcinomas.
        Head Neck. 2007; 29: 655-664
        • Chua T.C.
        • Merrett N.D.
        Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes – a systematic review.
        Int. J. Cancer. 2012; 130: 2845-2856
        • Wolff A.C.
        • Hammond M.E.
        • Hicks D.G.
        • Dowsett M.
        • McShane L.M.
        • Allison K.H.
        • et al.
        Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
        J. Clin. Oncol. 2013; 31: 3997-4013
        • Erickson B.K.
        • Zeybek B.
        • Santin A.D.
        • Fader A.N.
        Targeting human epidermal growth factor receptor 2 (HER2) in gynecologic malignancies.
        Curr. Opin. Obstet. Gynecol. 2020; 32: 57-64
        • Morrison C.
        • Zanagnolo V.
        • Ramirez N.
        • Cohn D.E.
        • Kelbick N.
        • Copeland L.
        • et al.
        HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients.
        J. Clin. Oncol. 2006; 24: 2376-2385
        • Santin A.D.
        • Bellone S.
        • Van Stedum S.
        • Bushen W.
        • Palmieri M.
        • Siegel E.R.
        • et al.
        Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
        Cancer. 2005; 104: 1391-1397
        • Slomovitz B.M.
        • Broaddus R.R.
        • Burke T.W.
        • Sneige N.
        • Soliman P.T.
        • Wu W.
        • et al.
        Her-2/neu overexpression and amplification in uterine papillary serous carcinoma.
        J. Clin. Oncol. 2004; 22: 3126-3132
        • Erickson B.K.
        • Najjar O.
        • Damast S.
        • Blakaj A.
        • Tymon-Rosario J.
        • Shahi M.
        • et al.
        Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: a multi-institutional cohort study.
        Gynecol. Oncol. 2020; 159: 17-22
        • Fader A.N.
        • Roque D.M.
        • Siegel E.
        • Buza N.
        • Hui P.
        • Abdelghany O.
        • et al.
        Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2/neu.
        J. Clin. Oncol. 2018; 36: 2044-2051
        • Bartley A.N.
        • Washington M.K.
        • Colasacco C.
        • Ventura C.B.
        • Ismaila N.
        • Benson 3rd, A.B.
        • et al.
        HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology.
        J. Clin. Oncol. 2017; 35: 446-464
        • Wolff A.C.
        • Hammond M.E.
        • Schwartz J.N.
        • Hagerty K.L.
        • Allred D.C.
        • Cote R.J.
        • et al.
        American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
        J. Clin. Oncol. 2007; 25: 118-145
        • Wolff A.C.
        • Hammond M.E.H.
        • Allison K.H.
        • Harvey B.E.
        • Mangu P.B.
        • Bartlett J.M.S.
        • et al.
        Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.
        Arch. Pathol. Lab. Med. 2018; 142: 1364-1382
        • Marabelle A.
        • Le D.T.
        • Ascierto P.A.
        • Di Giacomo A.M.
        • De Jesus-Acosta A.
        • Delord J.P.
        • et al.
        Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study.
        J. Clin. Oncol. 2020; 38: 1-10
        • Finotello F.
        • Mayer C.
        • Plattner C.
        • Laschober G.
        • Rieder D.
        • Hackl H.
        • et al.
        Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data.
        Genome Med. 2019; 11
        • Woo J.W.
        • Lee K.
        • Chung Y.R.
        • Jang M.H.
        • Ahn S.
        • Park S.Y.
        The updated 2018 American Society of Clinical Oncology/College of American Pathologists guideline on human epidermal growth factor receptor 2 interpretation in breast cancer: comparison with previous guidelines and clinical significance of the proposed in situ hybridization groups.
        Hum. Pathol. 2020; 98: 10-21
        • de Melo Gagliato D.
        • Jardim D.L.
        • Marchesi M.S.
        • Hortobagyi G.N.
        Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer.
        Oncotarget. 2016; 7: 64431-64446
        • Yakes F.M.
        • Chinratanalab W.
        • Ritter C.A.
        • King W.
        • Seelig S.
        • Arteaga C.L.
        Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.
        Cancer Res. 2002; 62: 4132-4141
        • Loibl S.
        • von Minckwitz G.
        • Schneeweiss A.
        • Paepke S.
        • Lehmann A.
        • Rezai M.
        • et al.
        PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.
        J. Clin. Oncol. 2014; 32: 3212-3220
        • Loibl S.
        • Darb-Esfahani S.
        • Huober J.
        • Klimowicz A.
        • Furlanetto J.
        • Lederer B.
        • et al.
        Integrated analysis of PTEN and p4EBP1 protein expression as predictors for pCR in HER2-positive breast cancer.
        Clin. Cancer Res. 2016; 22: 2675-2683
        • Buza N.
        • Euscher E.D.
        • Matias-Guiu X.
        • McHenry A.
        • Oliva E.
        • Ordulu Z.
        • et al.
        Reproducibility of scoring criteria for HER2 immunohistochemistry in endometrial serous carcinoma: a multi-institutional interobserver agreement study.
        Mod. Pathol. 2021; 34: 1194-1202
        • Fleming G.F.
        • Sill M.W.
        • Darcy K.M.
        • McMeekin D.S.
        • Thigpen J.T.
        • Adler L.M.
        • et al.
        Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study.
        Gynecol. Oncol. 2010; 116: 15-20
        • Fader A.N.
        • Roque D.M.
        • Siegel E.
        • Buza N.
        • Hui P.
        • Abdelghany O.
        • et al.
        Randomized phase II trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-trastuzumab in advanced (Stage III-IV) or recurrent uterine serous carcinomas that overexpress Her2/Neu (NCT01367002): updated overall survival analysis.
        Clin. Cancer Res. 2020; 26: 3928-3935
        • Bang Y.J.
        • Van Cutsem E.
        • Feyereislova A.
        • Chung H.C.
        • Shen L.
        • Sawaki A.
        • et al.
        Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
        Lancet. 2010; 376: 687-697